Celgene drops patent suit against Dr Reddy’s over Revlimid generic

Bristol-Myers Squibb 2022-02-25 11:15 am By Cat Fredenburgh | Melbourne

Please login to bookmark

Bristol-Myers Squibb unit Celgene has dropped a lawsuit accusing Indian generics company Dr Reddy’s Laboraties of threatening to infringe its patent for Revlimid with the planned launch of a generic version of the blockbuster cancer drug in Australia.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au